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While nephrologists often observe reduced hematocrit associated with inhibitors o f  angiotensin-con­
verting enzyme (ACE), the basis for this effect is not well understood. We now report that two strains 
o f ACE knockout mice have a normocytic anemia associated with elevated plasma erythropoietin lev­
els. 51Cr labeling o f  red cells showed that the knockout mice have a normal total blood volume but a 
reduced red cell mass. ACE knockout mice, which lack tissue ACE, are anemic despite having normal 
renal function. These mice have increased plasma levels o f  the peptide acetyl-SDKP, a possible stem 
cell suppressor. However, they also show low plasma levels o f  angiotensin II. Infusion o f  angiotensin 
II for 2 weeks increased hematocrit to near normal levels. These data suggest that angiotensin II facil­
itates erythropoiesis, a conclusion with implications for the management o f  chronically ill patients 
on inhibitors o f  the renin-angiotensin system.
J. Clin. Invest. 106:1391-1398 (2000).
Introduction
The renin-angiotensin system plays a critical role in 
blood pressure regulation and fluid hemodynamics. 
Pharmacologic inhibitors of this system are routinely 
used to treat hypertension and congestive heart failure. 
One o f the m ost controversial effects o f the renin- 
angiotensin system has been the interplay of this system 
with erythrocyte production. A variety o f clinical reports 
have noted an association between activation o f the 
renin-angiotensin system and increased erythropoiesis 
(1-3). These studies have come from analyses of patients 
w ith a variety o f chronic diseases including chronic 
obstructive pulmonary disease, heart failure, and renal 
transplantation. O ther investigators have suggested a 
link between angiotensin-converting enzyme (ACE) 
inhibitors and worsened anemia, particularly in patients 
w ith chronic renal failure (4-6). While research has 
focused on the interplay o f the renin-angiotensin sys­
tem and erythropoietin, no mechanistic explanation for 
these observations has been generally accepted.
Central to the renin-angiotensin system is ACE, a pep­
tidase that converts angiotensin I to angiotensin II (7). 
In  mammals, m ost ACE is bound to tissues such as 
endothelium, bu t enzymatic cleavage results in a circu­
lating form w ithin plasma. In vitro, ACE is capable of 
cleaving many small peptides besides angiotensin I. 
However, in vivo, with the exception o f bradykinin, the 
significance o f nonangiotensin peptides as ACE sub­
strates is not well understood. ACE is a protein with two 
independent catalytic domains. While bo th  catalytic
sites hydrolyze angiotensin I w ith roughly equal effi­
ciency, the amino- and carboxy-terminal catalytic 
domains differ in their rate constants for other peptides.
Using targeted hom ologous recom bination in 
embryonic stem (ES) cells, our laboratory created two 
lines o f mice with modifications o f the ACE gene (8, 9). 
These animals are term ed ACE.1 and ACE.2. Mice 
homozygous for the ACE.1 allele (ACE.1 knockout 
mice) are null for all ACE production. They have a 
marked reduction o f blood pressure, and a renal lesion 
characterized by hypoplasia o f the renal m edulla and 
papilla. In contrast to this null phenotype, animals 
homozygous for the ACE.2 allele (ACE.2 knockout 
mice) have a partial restoration o f ACE activity. These 
animals express a truncated ACE protein containing 
only the am ino-term inal catalytic domain. Since this 
shortened ACE protein lacks the carboxy-terminal 
domain that normally anchors ACE to cell membranes, 
the ACE.2 protein is exported from cells into blood and 
other extracellular fluids. Thus, while the plasm a of 
ACE.2 mice converts angiotensin I to angiotensin II 
with about 34% o f the activity o f wild-type mouse plas­
ma, tissues such as the lung and kidney completely lack 
ACE protein or activity. The systolic blood pressure of 
ACE.2 knockout mice averaged 75 mmHg, as low as 
that o f the ACE.1 knockout animals.
Here, we investigate an unexpected finding concern­
ing the phenotypes of bo th  the ACE.1 and ACE.2 mice. 
These animals are anemic. ACE.2 knockout mice are a 
particularly useful model to study the role o f the renin-
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ACE.1 / ACE.2 - Hematocrit
ACE.1 KO ACE.1 WT ACE.1 HZ ACE.2 KO ACE.2 WT ACE.2 HZ
F igu re  1
Hematocrit. Tail vein blood was collected in to m icrocapillary tubes 
and the hematocrit was determined fo r ACE.1 and ACE.2 knockout 
(KO), w ild-type (W T), and heterozygous (HZ) mice. The number o f 
mice in each group was as follows: ACE.1 KO, 12; ACE.1 WT, 13; 
ACE.1 HZ, 11; ACE.2 KO, 24; ACE.2 WT, 15; ACE.2 HZ, 14. The 
reduction in hematocrit between knockout and w ild-type mice was 
highly significant, w ith  P < 0.0001 fo r both knockout genotypes as 
compared w ith control mice. No significant difference was observed 
between w ild-type and heterozygous mice. Data are presented as 
mean ± SE. RBC, red blood cell.
angiotensin system in erythropoiesis, since these mice 
have norm al renal development and glomerular func­
tion. O ur data suggest that the anemia associated with 
in terrup tion  o f the renin-angiotensin system results 
from  a lack o f angiotensin II production, supporting 
the concept tha t angiotensin II facilitates erythro- 
poiesis. These conclusions have im plications for the 
clinical m anagem ent o f chronically ill patients on 
inhibitors o f the renin-angiotensin system.
Methods
Generation o f  ACE.1 and ACE.2 mice. ACE knockout 
mouse strains were created using targeted homologous 
recombination in ES cells as previously described (8, 9). 
B oth strains were propagated by the breeding o f he t­
erozygotes, w ith periodic backcrossing to C57BL/6 
mice. The ACE.1 mice used in this paper were at the 6 th 
and 7th generations of backcross, while the ACE.2 mice 
were at the 3rd through 5th generations o f backcross. 
Genotyping o f  pups from  bo th  strains was by PCR 
analysis as previously described.
Hemoglobin and hematocrit. Blood samples were collect­
ed via the tail vein, and hemoglobin concentration was 
determined using a Hemocue p-hemoglobin photom e­
ter from  Auratech Inc. (Greensboro, N orth  Carolina, 
USA). Additional blood was collected in microcapillary 
tubes. These were centrifuged for 4 minutes at 12,000 g  
and placed into a m anual microcapillary reader for the 
determination of hematocrit.
Red cell indices and serum chemistries. ACE.1 and ACE.2 
mice were bled either by the tail vein or by cardiac punc­
ture. For the determination of mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH), and 
mean corpuscular hemoglobin concentration (MCHC), 
and reticulocyte counts, blood was collected into tubes 
containing potassium-EDTA to prevent clotting. For
other serum chemistries, blood was placed in  1.5-ml 
Eppendorf tubes, perm itted to clot, and then cen­
trifuged for the collection o f serum. All analyses were 
performed either at the clinical laboratories o f Emory 
University Hospital or at the veterinary division of 
Antech Diagnostics (Farmingdale, New York, USA).
Creatinine and creatinine clearance. Mice were placed in 
metabolic cages for 24 hours w ithout food bu t with 
water ad libitum. Total urine volume was measured. 
Urine creatinine concentration was determined using a 
Beckman LX20 (Beckman Coulter Inc., Fullerton, Cali­
fornia, USA). After the collection period, plasma creati­
nine concentration was determined in  venous blood 
obtained from the tail. The creatinine clearance was cal­
culated using the standard equation: creatinine clearance 
= (urine creatinine /  plasma creatinine) X urine volume.
Plasma erythropoietin, angiotensin I, and angiotensin II lev­
els. Mice were exsanguinated by cardiac puncture, and 
blood was collected on ice in tubes containing 1.6 
m g/m l potassium-EDTA, 100 |JM am astatin , 100 |JM 
bestatin, and 4 H-g/ml lisinopril (10). Plasma was frozen 
immediately after blood collection and stored frozen 
until assays were performed. Erythropoietin was meas­
ured using a radioim m unoassay kit (bioMerieux SA, 
Marcy-l’Etoile, France). Standard curves were obtained 
using hum an erythropoietin and recombinant murine 
erythropoietin (Boehringer M annheim  Corp., Meylan, 
France). The standard  curve w ith m urine erythropoi­
etin was strictly parallel to the standard  curve with 
hum an erythropoietin. Angiotensin I and angiotensin 
II were also measured by radioim m unoassay as previ­
ously described (11). The assay background was deter­
mined by measuring peptide levels in angiotensinogen 
knockout mice, animals genetically m odified to lack 
angiotensin I and angiotensin II. Background values 
were subtracted from  the ACE.1 and ACE.2 m easure­
ments to obtain the final data.
Acetyl-SDKP. Acetyl-SDKP was measured in plasma by 
a competitive enzyme immunoassay as previously 
described (12). Polyclonal antibodies were obtained after 
im m unization of acetyl-SDKP bound to Electrophorus 
electricus acetylcholinesterase. The lower lim it o f this 
assay was estimated as 0.2 nM.
Blood pressure determination . Systolic blood pressure 
analysis was determ ined using a Visitech Systems 
(Apex, N orth  Carolina, USA) autom ated tail cuff sys­
tem (13). All animals were trained for 5 days prior to 
data collection. They were then subjected to three sets 
o f da ta  acquisition each day for the next 4 days. The 
first set o f five data points was discarded whereas the 
next two sets o f ten measurements were kept and aver­
aged. D ata sets w ith a standard deviation greater than
9 m m Hg were no t considered. The measured systolic 
blood pressure for an anim al was the average blood 
pressure obtained over 4 days and consisted o f eight 
sets o f ten measurements.
Angiotensin II infusion into ACE.2 mice. The base-line 
blood pressure was measured for a cohort o f ten ACE.2 
knockout mice and six litterm ate wild-type mice. The
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mice were then bled from  the tail vein for determ ina­
tion o f hematocrit and plasma hemoglobin concentra­
tion. The mice were weighed, and Alzet m odel 1002 
osmotic m inipum ps (ALZA Corp., Palo Alto, Califor­
nia, USA) were implanted subcutaneously into the dor­
sum. Six ACE.2 knockout mice and six wild-type mice 
received m inipum ps delivering a final dose o f 0.3 
m g/kg/d  angiotensin II diluted in  sterile 0.9% saline. 
Four ACE.2 knockout mice received pum ps loaded 
only with saline. All mice received the infusion during 
14 days. The mice were retrained for blood pressure 
measurement during the last part o f the infusion. Final 
systolic blood pressure was measured during the last 4 
days o f the infusion. On day 14, each animal was bled 
from the tail vein for the determ ination o f hematocrit 
and plasma hemoglobin concentration.
Red cell mass. The m easurem ent o f red cell mass and 
blood volume in mice using 51Cr-labeled erythrocytes 
has been previously described (14, 15). Briefly, whole 
blood was harvested from  donor ACE.2 heterozygous 
mice and incubated w ith 100 |J.Ci N a51CrO4 for 30 
m inutes at room temperature. During the incubation, 
the tubes were gently inverted every 5 m inutes to 
ensure adequate mixing. The erythrocytes were then 
pelleted at 2500 g  for 10 m inutes and washed twice in 
PBS. Finally, they were resuspended to a hem atocrit 
o f approximately 50%.
ACE.2 mice were anesthetized w ith ketamine, 
xylazine, and bu to rphanol, and the carotid arteries 
were catheterized w ith M icro-Renathane tubing 
(Braintree Scientific Inc., Braintree, M assachusetts, 
USA) tapered in sesame oil heated to 200°C. The mice 
were infused w ith 100 |0.l o f  labeled erythrocytes, fol­
lowed by a flush  o f 300 |0.l heparin/PBS (2000 U/ml). 
After 10 m inutes, they were exsanguinated by cardio- 
centesis and their blood divided into 100 |0.l aliquots. 
One aliquot was used to determ ine the postinfusion 
hem atocrit. Two more were directly counted in  a Y 
counter, while the final two were centrifuged and
washed before being counted. D ata were adjusted for 
the infusion volume o f400 |0.l and then normalized for 
the weight o f the animals.
Results
Anemia. Evaluation o f ACE.1 and ACE.2 mice dem on­
strated a persistent anemia (Figure 1). Both wild-type 
mice and mice heterozygous for the ACE.1 or ACE.2 
m utation  had hem atocrits tha t averaged 47-50%. In 
contrast, the average hematocrits o f ACE.1 and ACE.2 
knockout mice were 39% and 38% respectively. This 
reduction was b o th  consistently observed and highly 
significant for bo th  knockout genotypes as compared 
with control mice (P < 0.0001). Hemoglobin levels were 
also reduced in  bo th  knockout genotypes (Table 1). 
There were no significant differences in MCV, MCH, 
and MCHC, indicating a normocytic, norm ochrom ic 
anemia. None o f the genotypes showed a gross abnor­
mality o f platelets or white cell number.
ACE.1 mice were used to study iron m etabolism  by 
evaluating serum iron, total iron binding capacity, and 
serum iron saturation. As presented in Table 1, the val­
ues for the ACE.1 knockout mice were no different from 
those measured in littermate wild-type or heterozygous 
animals. Stainable bone marrow iron was readily appar­
ent in both  ACE.1 and ACE.2 knockout mice (data not 
shown). These data argue against iron deficiency as the 
cause of anemia. At necropsy, the histologic appearance 
o f the bone marrow in knockout animals was no t dif­
ferent from the bone marrow of control mice. Specifi­
cally, the cellularity o f bone marrow from  knockout 
mice was greater than 95% with a myeloid-to-erythroid 
ratio o f 4:1. Megakaryocytes were relatively numerous 
and diffusely spaced. Normal m aturation was observed 
in myeloid, erythroid, and megakaryocytic lineages.
We also investigated hemolysis as a factor contribut­
ing to the anemia. This was evaluated in  ACE.1 and 
ACE.2 mice by studying serum  indirect bilirubin, lac­
tate dehydrogenase, and reticulocyte levels (Table 1). As
Table 1
Blood and serum chemistries o f  ACE.1 and ACE.2 mice
ACE.1 W T ACE.1 HZ ACE.1 KO ACE.2 W T ACE.2 HZ ACE.2 KO
H em oglob in  (g /d l) 15 .0  ± 0 .2  (13 ) 15.6  ± 0 .3  (11) 12 .0  ± 0 .3  (12 ) 14 .3  ± 0 .5  (15 ) 14 .8  ± 0 .4  (14 ) 11 .7  ± 0 .2  (24 )
M C V (fl) 4 5 .3  ± 1.2 (8) 4 5 .5  ± 0 .8 ( 8 ) 4 6 .7  ± 2 .5  (8) 54.1 ± 4 .2  (7) 5 5 .7  ± 5 .7 ( 6 ) 5 4 .4  ± 4 .2  (8)
M CH (pg) 15.3  ± 0 .6  (8) 15 .8  ± 0 .3  (8 ) 15 .8  ± 1 .0 (8 ) 16 .3  ± 0 .4  (7) 16.2  ± 0 .8  (6 ) 16 .0  ± 0 .4  (8)
M CH C  (g /d l) 3 3 .8  ± 1 .9 (8 ) 3 4 .7  ± 0 .8 ( 8 ) 3 3 .9  ± 1 .3  (8 ) 31.1 ± 2 .4 (7 ) 30 .5  ± 3 .0  (6 ) 3 0 .5  ± 2.2  (8)
R eticulocytes (%) 4 .4  ± 1.0 (8) 2.5 ± 0 .6  (7) 3.1 ± 0 .8 ( 8 ) 2.2  ± 0 .5  (8) ND 2.6 ± 0 .4  (12 )
LDH (U /l) 144 .5  ± 7 .7 (1 0 ) 18 5 .0  ± 2 2 .8 (1 0 ) 180 .3  ± 2 5 .9  (6) 181 .0  ± 1 9 .6 (8 ) 2 4 8 .4  ± 3 0 .0  (5) 1 7 5 .4  ± 3 3 .5  (8 )
Indirect bilirubin (m g /d l) 0 .4 3  ± 0 .0 3  (10 ) 0 .4 3  ± 0 .0 2  (11 ) 0 .4 8  ± 0 .0 4  (6) 0 .4 4  ± 0 .0 3  (8) 0 .4 8  ± 0 .0 7  (5) 0 .4 4  ± 0 .0 3  (8)
Serum  iron (|ag /d l) 1 3 3 .4  ± 4.1 (17 ) 143 .2  ± 6 .7 (1 5 ) 1 3 9 .4  ± 7 .2  (10 ) ND ND ND
T IB C (|ag /d l) 4 1 0 .8  ± 7 .4  (1 7 ) 3 9 1 .7  ± 8 .6  (15 ) 4 2 6 .9  ± 1 2 .3  (10 ) ND ND ND
% T ransferrin  sa tu ra tio n 3 2 .5  ± 1.1 (17 ) 37 .0  ± 2 .2  (15 ) 3 2 .8  ± 1 .8 (1 0 ) ND ND ND
A ngiotensin  II (p g /m l) 110  ± 1 5 (1 0 ) 128  ± 1 9 (1 1 ) 12 .5  ± 3 .0  (12) 105  ± 1 4 ( 1 3 ) 9 7  ± 16 (10 ) 2 2 .8  ± 4 .0  (11 )
A ngiotensin  I (p g /m l) 992  ± 200  (10 ) 1852 ± 205  (11 ) 21 5 6  ± 253  (12 ) 7 9 9  ± 1 1 2 ( 1 3 ) 1281 ± 233  (10 ) 1 4 5 4 ±  22 6  (11)
Ang ll/A ng I ra tio 0 .13  ± 0 .0 3  (10 ) 0 .0 7 ±  0.01 (1 1 ) 0 .0 0 5  ± 0 .0 0 1  (12 ) 0.15  ± 0 .0 2  (13) 0 .0 8  ± 0 .0 1  (10 ) 0 .0 1 6  ± 0 .0 0 2  (11 )
Wild-type (WT), heterozygote (HZ), and knockout (KO) mice were studied for the param eters listed in the table. The num ber o f  animals in each group is given in 
parentheses. D ata are presented as the m ean + SEM. Differences in MCV, MCH, and MCHC for ACE.1 and ACE.2 wild-type mice are attributable to  a  different 
commercial laboratory per form ing the m easurements for each strain. LDH, lactate dehydrogenase; TIBC, total iron-binding capacity; ND, no data; Ang, angiotensin.
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F igu re  2
Plasma erythropoietin. Anesthetized mice were bled by cardiac punc­
ture and plasma was immediately frozen. Erythropoietin levels were 
determined by radioimmunoassay. The number o f  mice in each group 
was as follows: ACE.1 KO, 10; ACE.1 WT, 9; ACE.1 HZ, 12; ACE.2 KO, 
8; ACE.2 WT, 13; ACE.2 HZ, 9. The P value comparing ACE.1 knock­
out mice with wild-type mice is less than 0.01. A similar comparison o f 
ACE.2 knockout mice w ith wild-type gave P < 0.05. Thus, the anemia 
present in ACE.1 and ACE.2 knockout mice was associated w ith ele­
vated plasma levels o f  erythropoietin. Data are presented as mean ± SE.
with the evaluation o f iron, we found no significant dif­
ferences in  these indices between knockout mice and 
bo th  litterm ate wild-type and heterozygous animals. 
While serum haptoglobin is useful in  assessing hem ol­
ysis in hum ans, this m easurement is no t easily applied 
to mice, since even wild-type mice have undetectable 
serum haptoglobin levels. Thus, our data suggest that 
hemolysis does no t play a m ajor role in  the anemia 
observed in these animals.
Erythropoietin. In the evaluation o f  hum an anemia 
due to inhibition o f the renin-angiotensin system, ery­
thropoietin  levels have been controversial; some 
groups have reported lowered levels, while others find 
no significant change (4). To measure plasma erythro­
poietin in ACE.1 and ACE.2 mice, animals were exsan­
guinated by cardiac puncture and erythropoietin was 
measured by radioimmunoassay (Figure 2). These data 
show th a t ACE.1 and ACE.2 knockout mice have sig­
nificantly higher plasm a erythropoietin  levels than  
wild-type or heterozygous litterm ate controls. For 
example, ACE.1 knockout mice averaged 2.72 ± 0.29 
m U /m l, while wild-type mice averaged 1.56 ± 0.16 
m U /m l (P < 0.01). A sim ilar com parison o f ACE.2
F igu re  3
Renal function, (a) Serum creatinine was measured from venous blood 
obtained from the tail. The number o f  mice in each group was as fo l­
lows: ACE.1 KO, 11; ACE.1 WT, 12; ACE.1 HZ, 14; ACE.2 KO, 30; 
ACE.2 WT, 50; ACE.2 HZ, 50. (b) The creatinine clearance was meas­
ured as described in Methods. The number o f  mice in each group was 
as follows: ACE.1 KO, 5; ACE.1 WT, 6; ACE.1 HZ, 6; ACE.2 KO, 30; 
ACE.2 WT, 21; ACE.2 HZ, 19. All data are presented as mean ± SE. 
ACE.1 mice have a significant elevation o f  serum creatinine as com ­
pared with wild-type and heterozygous mice (P<  0.01). They also have 
a significant reduction o f  creatinine clearance as compared w ith these 
same contro l animals (P < 0.05). In contrast, ACE.2 knockout mice 
have no evidence o f  renal failure in that their serum creatinine and cre­
atinine clearance values were not significantly different from wild-type 
littermate controls. While the creatinine clearance o f  ACE.1 and ACE.2 
heterozygous mice is somewhat elevated above the levels o f  wild-type 
mice, these differences do not reach statistical significance. The d if­
ference in serum creatinine between ACE.1 wild-type mice and ACE.2 
wild-type mice is probably due to the use o f  different reference labo­
ratories to  obtain these data.
ACE.1 / ACE.2 - Plasm a erythropoietin
ACE.1 KO ACE.1 WT ACE.1 HZ ACE.2 KO ACE.2 WT ACE.2 HZ
knockout mice (2.46 ± 0.42 m U/m l) w ith wild-type 
(1.59 ± 0.24 m U/m l) was also significant (P < 0.05). 
While the ACE.1 knockout animals tended to have 
higher serum  erythropoietin  levels than  the ACE.2 
knockout animals, this difference did no t achieve sta­
tistical significance. Thus, despite a relatively elevated 
plasm a erythropoietin, ACE.1 and ACE.2 knockout 
mice are anemic.
Renal function. We considered renal failure as a possi­
ble explanation for anem ia in these mice. In order to 
compare the renal function o f the two strains o f mice, 
we evaluated the serum creatinine and creatinine clear­
ance o f a large cohort o f animals (Figure 3, a and b). 
These data show a discrepancy between the renal func­
tion o f the ACE.1 and ACE.2 knockout mice. ACE.1 
knockout mice have chemical evidence o f renal failure 
as indicated by an elevation o f serum creatinine and a 
significant reduction o f renal creatinine clearance. For 
instance, the creatinine clearance o f ACE.1 knockout 
mice was 138 ± 15 ml/d, while littermate wild-type mice 
had a creatinine clearance o f 272 ± 46 m l/d  (P < 0.05). 
In contrast, ACE.2 knockout mice had no evidence of 
renal failure, in tha t their serum creatinine and creati-
a  ACE.1 / ACE.2 - Serum creatinine“  0.61
ACE.1 KO ACE.1 WT ACE.1 HZ ACE.2 KO ACE.2 WT ACE.2 HZ
[ j  ACE.1 /  ACE.2 - Creatinine clearance
ACE.1 KO ACE.1 WT ACE.1 HZ ACE.2 KO ACE.2 WT ACE.2 HZ
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nine clearance values were no t significantly different 
from  wild-type litterm ate controls. The difference in 
renal function  between ACE.1 and ACE.2 knockout 
mice is consistent w ith the known renal histology o f 
the two strains of mice (9). ACE.1 knockout mice have 
a renal lesion typified by medullary underdevelopment. 
In contrast, the kidneys of m ost ACE.2 knockout mice 
show norm al renal medullary development. As antici­
pated, heterozygous mice o f bo th  ACE strains have 
renal function indistinguishable from that o f wild-type 
mice. Thus, while renal failure may be a potential expla­
nation  for anem ia in the ACE.1 knockout mice, it 
seems very unlikely that renal failure is the explanation 
for the anem ia observed in  ACE.2 knockout animals.
Plasma peptide levels. An im portant difference between 
ACE.1 and ACE.2 knockout mice is the effect o f the 
m utated  ACE  gene. ACE.1 knockout mice are null for 
all ACE activity. In contrast, ACE.2 knockout mice lack 
tissue-bound ACE b u t do have some restoration of 
ACE activity in plasma. Despite this difference, both  
the blood pressure and the degree of anemia present in 
these two strains o f knockout mice are essentially indis­
tinguishable. To investigate this in detail, we measured 
the plasm a levels o f the peptides angiotensin I and 
angiotensin II by radioimmunoassay (Figure 4, a and b, 
and Table 1). As an im portant control for this study, we 
determ ined angiotensin I and angiotensin II levels in 
the plasma o f angiotensinogen knockout mice. These 
animals genetically lack angiotensin I and angiotensin 
II, allowing us to determine the cross-reactivity o f our 
assay for extraneous peptides. This value was subtract­
ed from the ACE.1 and ACE.2 measurements to obtain 
the final data. As one would anticipate, both  ACE.1 and 
ACE.2 knockout mice have elevated levels of 
angiotensin I and much-decreased angiotensin II. In 
contrast, heterozygous mice have plasm a angiotensin 
II levels tha t are no t significantly different from those 
o f wild-type mice. They achieve this, and a norm al 
blood pressure, through the upregulation o f 
angiotensin I levels (Figure 4b, Table 1). There is a small 
difference in the plasm a levels o f  angiotensin II 
between ACE.1 and ACE.2 knockout mice (12.5 ± 2.9 vs. 
22.8 ± 4.0 pg/ml, P  < 0.05). While this difference is sig­
nificant, knockout mice o f both  strains possess only a 
small fraction o f the plasm a angiotensin II present in 
wild-type mice. Interestingly, while angiotensin II lev­
els in ACE.1 knockout mice are reduced by about 90%, 
they are no t zero, probably because o f  non-ACE- 
dependent degradation o f the elevated levels of 
angiotensin I present in these animals.
Acetyl-SDKP is a peptide that is normally degraded by 
the amino-terminal catalytic region o f ACE. While not 
extensively studied, this peptide has been implicated as 
a bone marrow stem cell suppressor (16-18). Using a 
radioimmunoassay, we studied plasma acetyl-SDKP lev­
els in the ACE.1 and ACE.2 mice (Figure 5). Both the 
ACE.1 and ACE.2 knockout mice showed a very signifi­
cant elevation o f plasma acetyl-SDKP as compared with 
wild-type or heterozygous mice (P < 0.0001). In addi­
tion, there was a significant difference between the 
plasma levels of the ACE.1 knockout mice and those of 
the ACE.2 knockout mice (3.5 ± 0.4 nM vs. 2.2 ± 0.2 nM, 
P  < 0.01). One m ight anticipate such a difference in 
acetyl-SDKP peptide levels between the ACE.1 and 
ACE.2 knockout mice, since previous analysis has 
shown that the plasma activity of ACE.2 knockout mice, 
as measured with the amino-terminal-specific substrate 
acetyl-SDKP, is almost 90% that o f plasm a from  wild- 
type mice (9). Thus, ACE.1 and ACE.2 knockout mice 
have an equivalent degree o f anemia, despite the dis­
parity o f plasm a acetyl-SDKP levels. While one may 
hypothesize that acetyl-SDKP is not the primary cause 
of anemia in these mice, formal studies, such as investi­
gations o f the kinetics o f SDKP inhibition, need to be 
performed to fully evaluate this question.
Red cell mass. A critical question concerning the ane­
m ia present in  ACE knockout mice is the effect of 
vasodilation in these animals. A ngiotensin II is a 
po ten t vasoconstrictor, and the m arked reduction of
a  ACE.1/ACE.2 - Plasma angiotensin II
ACE.1 KO ACE.1 WT ACE.1 HZ ACE.2 KO ACE.2 WT ACE.2 HZ
b  020 ACE.1/ACE.2-Plasma Ang ll/Ang I ratio
ACE.1 KO ACE.1 WT ACE.1 HZ ACE.2 KO ACE.2 WT ACE.2 HZ
F igu re  4
Plasma angiotensin peptide levels. Anesthetized mice were bled by car­
diac puncture and plasma was immediately frozen. Plasma 
angiotensin I and angiotensin ll peptide levels were determined by 
radioimmunoassay. The number o f  mice in each group was as follows: 
ACE.1 KO, 12; ACE.1 WT, 10; ACE.1 HZ, 11; ACE.2 KO, 11; ACE.2 
W T, 13; ACE.2 HZ, 10. (a) Both ACE.1 and ACE.2 knockout mice 
have a marked reduction o f  plasma angiotensin ll, w ith  P < 0.0001 
compared with either wild-type o r heterozygous mice, (b) Both ACE.1 
and ACE.2 knockout mice have a marked reduction o f  the angiotensin 
ll /  angiotensin I ratio. This is due to  a reduction o f  plasma 
angiotensin ll and an elevation o f  plasma angiotensin I levels (see 
Table 1). While ACE.1 and ACE.2 heterozygous mice have normal lev­
els o f  plasma angiotensin ll (a), the elevation o f  angiotensin I present 
in these mice resulted in a significant reduction o f  the angiotensin ll 
/  angiotensin I ratio as compared with wild-type mice (P<0.01). Data 
are presented as mean ± SE.
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F igu re  5
Acetyl-SDKP. Venous blood was obtained from  the ta il and plasma 
was immediately frozen. Acetyl-SDKP peptide levels were measured by 
radioimmunoassay. The number o f  mice in each group was as follows: 
ACE.1 KO, 7; ACE.1 WT, 6; ACE.1 HZ, 6; ACE.2 KO, 18; ACE.2 WT, 
9; ACE.2 HZ, 10. Both ACE.1 and ACE.2 knockout mice have an ele­
vation o f  plasma acetyl-SDKP as compared w ith  w ild-type o r het­
erozygous mice. The highest levels o f  peptide were present in the 
ACE.1 knockout mice, animals completely null fo r ACE activity. Data 
are presented as the means ± SE.
this peptide in  the ACE knockout mice should p ro ­
mote vasodilation. Hypothetically, this m ight lead to 
volume expansion and a dilu tional anemia. We used 
51Cr labeling o f red blood cells to determine blood vol­
ume, red blood cell volume, and plasm a volume in 
ACE.2 knockout mice (Figure 6). ACE.2 knockout 
mice have a total blood volume comparable w ith that 
o f wild-type mice (58 p l/g  vs. 56 pl/g). This value is 
similar to the to tal blood volumes o f several strains of 
mice previously reported in  the literature (14, 19). 
However, ACE.2 knockout mice have a 25% reduction 
o f red cell mass as compared w ith wild-type mice (22.7 
p l/g  ± 1.1 p l/g  vs. 30.3 p l/g  ± 1.7 pl/g, P  < 0.01). These 
data show th a t the anem ia observed in ACE.2 knock­
out mice is real and no t due to excessive volume expan­
sion. Thus, our data  indicate th a t ACE.2 knockout 
mice have roughly an equivalent reduction o f  bo th  
hem atocrit (Figure 1) and red cell mass.
Response o f  anemia to angiotensin II . In evaluating the 
anem ia in the ACE.2 knockout mice, we questioned 
whether the anemia was due to the lack o f angiotensin 
II production or to an effect o f some other peptide such 
as acetyl-SDKP accumulation. This can be experimen­
tally investigated by infusing angiotensin II into ACE.2 
knockout mice and examining the effect on hem at­
ocrit. If  the anem ia is the result o f  a nonangiotensin 
peptide such as acetyl-SDKP, then angiotensin II pep­
tide infusion should have a m inimal effect. An im por­
tan t prelim inary study was to determine the dose of 
angiotensin II sufficient to raise the blood pressure of 
ACE.2 knockout animals to roughly wild-type levels. 
ACE.2 knockout mice are far more sensitive to exoge­
F igu re  6
Red cell mass. W hole blood was obtained by cardiac puncture from 
donor ACE.2 heterozygous mice. A fter labeling w ith  51Cr, an a liquot 
was infused via a carotid  artery catheter. A fte r a llow ing fo r equ ili­
bration, blood was obtained by cardiac puncture and used to  deter­
mine to ta l blood volume and to ta l red cell volume. An implied plas­
ma volume was then calculated. All data were normalized fo r the 
weight o fth e  animal. The number o f  mice in each group was as fo l­
lows: ACE.2 KO, 7; ACE.2 W T, 7. W hile the blood volume o f  ACE.2 
knockout mice is equivalent to  that o fw ild -type  mice, the data show 
tha t the ACE.2 knockout mice have roughly a 25% reduction o f  red 
cell mass ( P < 0.01). Data are presented as mean ± SE.
ACE.1 / ACE.2 - Acetyl-SDKP
ACE.1 KO ACE.1 WT ACE.1 HZ ACE.2 KO ACE.2 WT ACE.2 HZ
nous angiotensin II than  wild-type mice. As an exam­
ple, the constant infusion o f 1.1 m g/kg/d, a dose of 
angiotensin II often used to raise the blood pressure of 
rodents by roughly 40 mmHg, caused extreme hyper­
tension and death in ACE.2 knockout mice. Finally, we 
determined tha t the infusion by osmotic m inipum p of 
0.3 m g/kg/d o f angiotensin II for 2 weeks was well to l­
erated and raised the systolic blood pressure o f ACE.2 
knockout mice from 73 mm Hg to 131 mm Hg (Figure 
7A). This small dose o f angiotensin II had a m inimal 
effect on ACE.2 wild-type mice, raising systolic blood 
pressure from 106 m mHg to 114 mmHg.
A cohort o f  ACE.2 knockout mice was treated with 
either 0.3 m g/kg/d  angiotensin II or saline for 2 weeks 
(Figure 7). Systolic blood pressure and hem atocrit 
were determined immediately before and at the end of 
the infusion period. A group o f wild-type ACE.2 mice 
were treated in  a similar fashion. This study showed a 
m arked increase o f hem atocrit in  ACE.2 knockout 
mice receiving angiotensin II from  the preinfusion 
level o f 41.2 ± 1.0% to the postinfusion value o f 48.3 ±
0.8% (P < 0.001). Thus, treatm ent o f ACE.2 knockout 
mice w ith a low dose o f angiotensin II raised the 
blood pressure and corrected the hem atocrit to near 
wild-type levels. This study suggests th a t the anemia 
in ACE.2 knockout mice is directly related to the lack 
o f angiotensin II generation in  these animals.
Discussion
While the role o f  the renin-angiotensin  system in 
b lood pressure control is widely appreciated, there is 
no theoretical underp inn ing  to explain why mice
ACE.2 - 51Cr-labeled RBC infusion
ACE.2 KO ACE.2 WT ACE.2 KO ACE.2 WT ACE.2 KO ACE.2 WT
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deficient in  ACE present w ith  anem ia. This anem ia 
parallels a variety o f clinical studies suggesting th a t 
the renin-angiotensin system plays a role in  hum an  
erythrocyte production. For instance, an early study 
o f  the ACE in h ib ito r enalapril in  b o th  hypertensive 
patients and norm al volunteers found a sm all reduc­
tio n  o f  hem atocrit levels (20). M any m ore studies 
have examined the effect o f  ACE inhibitors and AT1 
receptor antagonists in  renal dialysis and renal trans­
p lan tation  patients. In particular, a substantial nu m ­
ber o f  clinical studies have com m ented th a t ACE 
inhibitors are often effective in  reducing the erythro- 
cytosis observed after renal transp lan ta tion  (21-25). 
These studies have disagreed as to  the role o f  ACE 
inhib ito rs on ery thropoietin  p roduction  and effec­
tiveness (4). Some groups suggest th a t ACE 
inhib ito rs reduce ery thropoietin  levels or induce 
resistance to ery thropoietin  (6, 22, 23, 26). O ther 
studies find no causative link between erythropoietin 
and the anem ia induced by ACE inh ib ito rs or AT1 
receptor antagonists (3, 24, 27, 28).
ACE.2 knockout mice are an excellent m odel sys­
tem  for studying the role o f  the renin-angiotensin 
system in erythropoiesis (9). These mice have stable 
renal function  sim ilar to th a t o f wild-type mice. The 
mice do no t have a chronic disease, and they do no t 
take m edications w ith  secondary actions. Yet they 
consistently present w ith anem ia characterized by a 
reduction  o f red cell mass o f approxim ately 20%. 
These mice have adequate iron  stores and  no evi­
dence o f  hemolysis. Serum  erythropoietin  levels are 
elevated as com pared w ith  contro l mice. W hether 
this is an appropriate  level o f  elevation given the 
degree o f anem ia is d ifficu lt to  evaluate. W hat we 
have observed is th a t ACE.2 knockout mice respond 
to pharm acologic adm in istra tion  o f recom binant 
ery thropoietin  w ith a brisk elevation o f hem atocrit 
(data n o t shown). Thus, the anem ia in  ACE.2 mice 
does no t appear to be associated w ith a gross reduc­
tion  o f  erythropoietin  levels or responsiveness.
Strikingly, ACE.2 knockout mice respond to a small 
dose o f angiotensin II by increasing hem atocrit to near 
norm al levels. This implies that, in  response to 
angiotensin II, there is an increase o f red blood cell 
mass and a decrease of plasma volume to near normal 
levels. Thus, our data suggest that the anemia in these 
animals results from  a lack o f angiotensin II, and not 
from  the effects o f a nonangiotensin peptide such as 
the accum ulation o f acetyl-SDKP. M rug et al. studied 
the effect o f angiotensin II on the proliferation of ery- 
throid  progenitors and reported th a t angiotensin II 
enhanced erythropoietin-stim ulated erythroid prolif­
eration in vitro (29). This group also showed that burst- 
form ing units-erythroid  (BFU-E) colonies possess 
angiotensin II AT1 receptors, and th a t the effect of 
angiotensin II was blocked by the ATi receptor antago­
n ist losartan. Erythropoietin, the m ain stim ulator of 
erythrocyte form ation, binds a surface receptor and 
signals to the nucleus through the Jak-STAT pathway
(30). This signaling pathway is im portant, as evidenced 
by the embryonic lethality o f  Jak2 kinase knockout 
mice due to gross defects in erythrocyte generation (31, 
32). There is now abundant evidence tha t angiotensin
II, acting through the AT1 receptor, also stimulates Jak2 
kinase activation and STAT nuclear translocation (33, 
34). W hether the lack o f angiotensin II-m ediated Jak- 
STAT signaling contributes to the anemia observed in 
ACE knockout mice is no t known.
ACE inhibitors and AT1 receptor antagonists are 
widely used in clinical medicine. While the hematocrit- 
lowering effects of these agents in hypertensive patients 
is typically insignificant, this may no t be true in 
patients w ith chronic diseases associated with anemia. 
In such patients, clinicians need to be aware tha t 
angiotensin II appears to play a role in  erythropoiesis.
F igu re  7
Angiotensin 11 infusion increases hematocrit. A cohort o f  w ild-type 
and ACE.2 knockout mice were evaluated fo r systolic blood pressure 
and hem atocrit. Animals were then im planted w ith  osmotic 
m inipumps delivering either angiotensin 11 (+ Ang) o r vehicle (Con­
tro l). A fter 2 weeks, blood pressure and hematocrit were reassessed, 
(a) The systolic blood pressure o f  the mice before and after 
angiotensin 11 infusion. The number o f  mice in each group was as fo l­
lows: ACE.2 WT, 6; ACE.2 KO + Ang, 6; ACE.2 KO contro l, 4. In fu­
sion o f  small amounts ofangiotensin 11 raised the blood pressure o f  
ACE.2 knockout mice to  levels comparable w ith those o f  w ild-type 
mice. (b )T h e  hematocrits o f  the mice described in a were studied 
before and after angiotensin 11 infusion. ACE.2 knockout mice treat­
ed w ith angiotensin 11 showed a significant increase o f  hem atocrit 
(P <  0.001) to  levels near those o fw ild -type  mice.
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